APO Research
Talk to an analyst

APO RESEARCH · REPORT

Injectable Anticoagulants

The injectable anticoagulants include low molecular weight heparin (LMWH) agents (dalteparin [Fragmin®], enoxaparin [Lovenox®]) and factor Xa inhibitors (fondaparinux [Arixtra®]).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The injectable anticoagulants include low molecular weight heparin (LMWH) agents (dalteparin [Fragmin®], enoxaparin [Lovenox®]) and factor Xa inhibitors (fondaparinux [Arixtra®]).

In general, the injectable anticoagulants are Food and Drug Administration (FDA)-approved for prophylaxis and/or treatment of venous thromboembolism.

Selected research

Market Outlook & Growth Opportunities

Global Injectable Anticoagulants Market Outlook and Growth Opportunities 2026

2 January 2026190 pages

Choose your research edition.

Industry ResearchInjectable Anticoagulants Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Injectable Anticoagulants Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Injectable Anticoagulants Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Injectable Anticoagulants Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Injectable Anticoagulants Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The injectable anticoagulants include low molecular weight heparin (LMWH) agents (dalteparin [Fragmin®], enoxaparin [Lovenox®]) and factor Xa inhibitors (fondaparinux [Arixtra®]).

In general, the injectable anticoagulants are Food and Drug Administration (FDA)-approved for prophylaxis and/or treatment of venous thromboembolism.

Market competition is intense. Sanofi, Genentech (Roche), Boehringer Ingelheim and Pfizer, etc. are the leaders of the industry, with about 68% market shares.

Read the full market overview

North America is the largest consumption place, with a consumption market share nearly 34%. Following North America, Europe is the second largest consumption place with the consumption market share of 30%.

This report provides an overview of the global Injectable Anticoagulants market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Injectable Anticoagulants and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Injectable Anticoagulants revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Injectable Anticoagulants market.

Injectable Anticoagulants Segment by Company

Sanofi

Genentech (Roche)

Boehringer Ingelheim

Pfizer

The Medicines Company

Aspen

Otsuka

Injectable Anticoagulants Segment by Type

Low-Molecular-Weight Heparin (LMWH)

Direct Thrombin Inhibitor (DTI)

Others

Injectable Anticoagulants Segment by Application

VTE

ACS/MI

AF

Others

Injectable Anticoagulants Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Injectable Anticoagulants status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Injectable Anticoagulants key companies, revenue, market share, and recent developments.

3. To split the Injectable Anticoagulants breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Injectable Anticoagulants market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Injectable Anticoagulants significant trends, drivers, influence factors in global and regions.

6. To analyze Injectable Anticoagulants competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Injectable Anticoagulants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Injectable Anticoagulants and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Injectable Anticoagulants.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Injectable Anticoagulants industry.

Chapter 3: Detailed analysis of Injectable Anticoagulants company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Injectable Anticoagulants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Injectable Anticoagulants in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Injectable Anticoagulants Industry Trends Table 2. Injectable Anticoagulants Industry Drivers Table 3. Injectable Anticoagulants Industry Opportunities and Challenges Table 4. Injectable Anticoagulants Industry Restraints Table 5. Global Injectable Anticoagulants Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Injectable Anticoagulants Revenue Share by Company (2021-2026) Table 7. Global Injectable Anticoagulants Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Injectable Anticoagulants Key Company Manufacturing Base & Headquarters Table 9. Global Injectable Anticoagulants Company, Product Type & Application Table 10. Global Injectable Anticoagulants Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Injectable Anticoagulants by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Low-Molecular-Weight Heparin (LMWH) Table 15. Significant Companies of Direct Thrombin Inhibitor (DTI) Table 16. Significant Companies of Others Table 17. Global Injectable Anticoagulants Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Injectable Anticoagulants Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Injectable Anticoagulants Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Injectable Anticoagulants Sales Value Share by Type (2021-2026) Table 21. Global Injectable Anticoagulants Sales Value Share by Type (2027-2032) Table 22. Significant Companies of VTE Table 23. Significant Companies of ACS/MI Table 24. Significant Companies of AF Table 25. Significant Companies of Others Table 26. Global Injectable Anticoagulants Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Injectable Anticoagulants Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Injectable Anticoagulants Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Injectable Anticoagulants Sales Value Share by Application (2021-2026) Table 30. Global Injectable Anticoagulants Sales Value Share by Application (2027-2032) Table 31. Global Injectable Anticoagulants Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Injectable Anticoagulants Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Injectable Anticoagulants Sales Value Share by Region (2021-2026) Table 34. Global Injectable Anticoagulants Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Injectable Anticoagulants Sales Value Share by Region (2027-2032) Table 36. Global Injectable Anticoagulants Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Injectable Anticoagulants Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Injectable Anticoagulants Sales Value Market Share by Country (2021-2026) Table 39. Global Injectable Anticoagulants Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Injectable Anticoagulants Sales Value Market Share by Country (2027-2032) Table 41. Sanofi Company Information Table 42. Sanofi Business Overview Table 43. Sanofi Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Sanofi Injectable Anticoagulants Product Portfolio Table 45. Sanofi Recent Development Table 46. Genentech (Roche) Company Information Table 47. Genentech (Roche) Business Overview Table 48. Genentech (Roche) Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Genentech (Roche) Injectable Anticoagulants Product Portfolio Table 50. Genentech (Roche) Recent Development Table 51. Boehringer Ingelheim Company Information Table 52. Boehringer Ingelheim Business Overview Table 53. Boehringer Ingelheim Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Boehringer Ingelheim Injectable Anticoagulants Product Portfolio Table 55. Boehringer Ingelheim Recent Development Table 56. Pfizer Company Information Table 57. Pfizer Business Overview Table 58. Pfizer Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Pfizer Injectable Anticoagulants Product Portfolio Table 60. Pfizer Recent Development Table 61. The Medicines Company Company Information Table 62. The Medicines Company Business Overview Table 63. The Medicines Company Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. The Medicines Company Injectable Anticoagulants Product Portfolio Table 65. The Medicines Company Recent Development Table 66. Aspen Company Information Table 67. Aspen Business Overview Table 68. Aspen Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Aspen Injectable Anticoagulants Product Portfolio Table 70. Aspen Recent Development Table 71. Otsuka Company Information Table 72. Otsuka Business Overview Table 73. Otsuka Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Otsuka Injectable Anticoagulants Product Portfolio Table 75. Otsuka Recent Development Table 76. Research Programs/Design for This Report Table 77. Authors List of This Report Table 78. Secondary Sources Table 79. Primary Sources List of Figures Figure 1. Injectable Anticoagulants Product Image Figure 2. Global Injectable Anticoagulants Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Injectable Anticoagulants Market Size (2021-2032) & (US$ Million) Figure 4. Global Injectable Anticoagulants Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Low-Molecular-Weight Heparin (LMWH) Image Figure 8. Direct Thrombin Inhibitor (DTI) Image Figure 9. Others Image Figure 10. Global Injectable Anticoagulants Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Injectable Anticoagulants Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Injectable Anticoagulants Sales Value Share by Type (2021-2032) Figure 13. VTE Image Figure 14. ACS/MI Image Figure 15. AF Image Figure 16. Others Image Figure 17. Global Injectable Anticoagulants Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Injectable Anticoagulants Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Injectable Anticoagulants Sales Value Share by Application (2021-2032) Figure 20. Global Injectable Anticoagulants Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Injectable Anticoagulants Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Injectable Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 23. North America Injectable Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Injectable Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Injectable Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Injectable Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Injectable Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Injectable Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 29. South America Injectable Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Injectable Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Injectable Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Low-Molecular-Weight Heparin (LMWH)
  • Direct Thrombin Inhibitor (DTI)
  • Others
Applications
  • VTE
  • ACS/MI
  • AF
  • Others
Companies covered
  • Sanofi
  • Genentech (Roche)
  • Boehringer Ingelheim
  • Pfizer
  • The Medicines Company
  • Aspen
  • Otsuka

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Injectable Anticoagulants Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Injectable Anticoagulants Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Injectable Anticoagulants Market Dynamics
  1. 2.1 Injectable Anticoagulants Industry Trends
  2. 2.2 Injectable Anticoagulants Industry Drivers
  3. 2.3 Injectable Anticoagulants Industry Opportunities and Challenges
  4. 2.4 Injectable Anticoagulants Industry Restraints
3 Injectable Anticoagulants Market by Company
  1. 3.1 Global Injectable Anticoagulants Company Revenue Ranking in 2025
  2. 3.2 Global Injectable Anticoagulants Revenue by Company (2021-2026)
  3. 3.3 Global Injectable Anticoagulants Company Ranking (2024-2026)
  4. 3.4 Global Injectable Anticoagulants Company Manufacturing Base and Headquarters
  5. 3.5 Global Injectable Anticoagulants Company Product Type and Application
  6. 3.6 Global Injectable Anticoagulants Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Injectable Anticoagulants Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Injectable Anticoagulants Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Injectable Anticoagulants Market by Type
  1. 4.1 Injectable Anticoagulants Type Introduction
  2. 4.1.1 Low-Molecular-Weight Heparin (LMWH)
  3. 4.1.2 Direct Thrombin Inhibitor (DTI)
  4. 4.1.3 Others
  5. 4.2 Global Injectable Anticoagulants Sales Value by Type
  6. 4.2.1 Global Injectable Anticoagulants Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Injectable Anticoagulants Sales Value by Type (2021-2032)
  8. 4.2.3 Global Injectable Anticoagulants Sales Value Share by Type (2021-2032)
5 Injectable Anticoagulants Market by Application
  1. 5.1 Injectable Anticoagulants Application Introduction
  2. 5.1.1 VTE
  3. 5.1.2 ACS/MI
  4. 5.1.3 AF
  5. 5.1.4 Others
  6. 5.2 Global Injectable Anticoagulants Sales Value by Application
  7. 5.2.1 Global Injectable Anticoagulants Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Injectable Anticoagulants Sales Value by Application (2021-2032)
  9. 5.2.3 Global Injectable Anticoagulants Sales Value Share by Application (2021-2032)
6 Injectable Anticoagulants Regional Value Analysis
  1. 6.1 Global Injectable Anticoagulants Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Injectable Anticoagulants Sales Value by Region (2021-2032)
  3. 6.2.1 Global Injectable Anticoagulants Sales Value by Region: 2021-2026
  4. 6.2.2 Global Injectable Anticoagulants Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Injectable Anticoagulants Sales Value (2021-2032)
  7. 6.3.2 North America Injectable Anticoagulants Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Injectable Anticoagulants Sales Value (2021-2032)
  10. 6.4.2 Europe Injectable Anticoagulants Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Injectable Anticoagulants Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Injectable Anticoagulants Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Injectable Anticoagulants Sales Value (2021-2032)
  16. 6.6.2 South America Injectable Anticoagulants Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Injectable Anticoagulants Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Injectable Anticoagulants Sales Value Share by Country, 2025 VS 2032
7 Injectable Anticoagulants Country-level Value Analysis
  1. 7.1 Global Injectable Anticoagulants Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Injectable Anticoagulants Sales Value by Country (2021-2032)
  3. 7.2.1 Global Injectable Anticoagulants Sales Value by Country (2021-2026)
  4. 7.2.2 Global Injectable Anticoagulants Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Injectable Anticoagulants Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Genentech (Roche)
  8. 8.2.1 Genentech (Roche) Company Information
  9. 8.2.2 Genentech (Roche) Business Overview
  10. 8.2.3 Genentech (Roche) Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Genentech (Roche) Injectable Anticoagulants Product Portfolio
  12. 8.2.5 Genentech (Roche) Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim Injectable Anticoagulants Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Injectable Anticoagulants Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 The Medicines Company
  26. 8.5.1 The Medicines Company Company Information
  27. 8.5.2 The Medicines Company Business Overview
  28. 8.5.3 The Medicines Company Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  29. 8.5.4 The Medicines Company Injectable Anticoagulants Product Portfolio
  30. 8.5.5 The Medicines Company Recent Developments
  31. 8.6 Aspen
  32. 8.6.1 Aspen Company Information
  33. 8.6.2 Aspen Business Overview
  34. 8.6.3 Aspen Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Aspen Injectable Anticoagulants Product Portfolio
  36. 8.6.5 Aspen Recent Developments
  37. 8.7 Otsuka
  38. 8.7.1 Otsuka Company Information
  39. 8.7.2 Otsuka Business Overview
  40. 8.7.3 Otsuka Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Otsuka Injectable Anticoagulants Product Portfolio
  42. 8.7.5 Otsuka Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst